Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for AF Recurrence Post-PVI
NCT04780438Phase 1Unknown
- Sponsor
- G. Gennimatas General Hospital
- Start
- Sep 2021
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Atrial fibrillation (AFib) comparing Dapagliflozin with Placebo (2 arms). Primary endpoint: Survival free of Atrial Fibrillation/Atrial Tachycardia recurrence at 18 months. Status: unknown.
02
Drugs
dapagliflozin
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT04780438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04780438.